Milestone Group Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,943 shares of the company’s stock after selling 1,687 shares during the period. Johnson & Johnson comprises about 0.3% of Milestone Group Inc.’s portfolio, making the stock its 25th largest position. Milestone Group Inc.’s holdings in Johnson & Johnson were worth $1,813,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Landmark Financial Advisors LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares in the last quarter. Paradigm Financial Advisors LLC grew its position in Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock valued at $350,000 after purchasing an additional 9 shares in the last quarter. Premier Asset Management LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after purchasing an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after purchasing an additional 14 shares in the last quarter. Finally, Halbert Hargrove Russell LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after purchasing an additional 15 shares in the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

Shares of Johnson & Johnson (NYSE JNJ) opened at $131.42 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The stock has a market cap of $354,163.94, a PE ratio of 336.97, a PEG ratio of 2.37 and a beta of 0.74. Johnson & Johnson has a 12 month low of $113.15 and a 12 month high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The company had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. Johnson & Johnson’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.58 EPS. research analysts forecast that Johnson & Johnson will post 8.08 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 861.54%.

JNJ has been the subject of a number of analyst reports. Jefferies Group raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $145.00 to $157.00 in a research report on Wednesday, October 11th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $129.62 target price for the company. in a research report on Friday, October 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $165.00 target price (up previously from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Finally, Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $146.16.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Sold by Milestone Group Inc.” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/02/08/johnson-johnson-jnj-shares-sold-by-milestone-group-inc.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.